Multiple Nonpainful Lesions: Your Dx?

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Your daily dose of the clinical news you may have missed.

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.